We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The American Medical Association (AMA) has announced a new policy on direct-to-consumer (DTC) advertising of implantable medical devices and prescription drugs.
A World Health Organization (WHO) initiative to loosen diagnostics and drug intellectual property (IP) laws in developing countries could lead diagnostics manufacturers to consider patent restrictions for their products and dampen their financial incentive to develop tests for diseases that are prevalent in poorer nations, an industry consultant suggests.
To meet demand for its sterile disposables products, MEDRAD, INC. will build a new Pennsylvania manufacturing facility and expects to hire 100 employees to staff it, with potential employment at the new facility anticipated to grow to 500 in five years.
Tulip BioMed, formerly known as Cell Bio-Systems, a developer of medical devices and patented technologies for the living tissue markets, including plastic, cosmetic, and orthopedic surgeries, today announced it has filed for a provisional patent on its hydrophilic coating process, which affects the manufacturing and use of cannulae.
German aerosol delivery firm PARI and UK medical gas provider BOC have agreed to jointly develop new gas-enabled drug delivery systems to help patients with compromised lung function.
BioMedica Diagnostic is to open a manufacturing facility in Ghana that will produce affordable laboratory equipment whilst meeting the need for a home grown African diagnostic solution for the Continent's medical problems.
Genesis, based in Redwood City, CA, emerges after two plus years of stealth development in the burgeoning market of occlusive vascular disease with two products to be introduced in the fall.
The FDA's Center for Devices and Radiological Health (CDRH) granted pre-market approval (PMA) for Abbott's Architect Ausab Reagent Kit, Architect Ausab Calibrators, and Architect Ausab Controls.
The FDA's Office of Combination Products has determined that Ceragenix Pharmaceuticals' Cerashield functions mostly as a device and will be reviewed as such by the FDA's Center for Devices and Radiological Health (CDRH) for lead review, the company announced.